Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference
NORWOOD, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 7th Annual Evercore HealthCONx Conference to be held December 3-5, 2024 in Coral Gables, FL.
馬薩諸塞州諾伍德，2024年11月21日(GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (納斯達克: CRBP) ("Corbus"或"公司"), 今天宣佈，corbus pharmaceuticals首席執行官尤瓦爾·科恩博士將參加於2024年12月3-5日在佛羅里達科勒爾蓋布爾舉辦的第7屆Evercore HealthCONx大會的爐邊聊天和一對一投資者會議。
7th Annual Evercore HealthCONx Conference
Format: Fireside chat and one-on-one investor meetings
Date: December 3, 2024
Time: 4:15 p.m. ET
Webcast: Click here
第七屆evercore HealthCONx大會
格式：爐邊聊天和一對一投資者會議
日期：2024年12月3日
時間:東部時間下午4:15
網絡直播：點擊這裏
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus' pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
關於Corbus
corbus pharmaceuticals控股公司是一家擁有多元化投資組合的腫瘤和肥胖公司，致力於幫助人們通過將創新的科學方法引入廣爲人知的生物途徑來戰勝嚴重疾病。Corbus的產品線包括CRb-701，一種針對癌細胞上Nectin-4表達的下一代抗體藥物結合物，用於釋放細胞毒性有效荷載，CRb-601，一種抗整合素單克隆抗體，可阻斷癌細胞上表達的TGFβ的激活，以及CRb-913，一種用於肥胖治療的高度外周限制的CB1受體反向激動劑。Corbus總部位於馬薩諸塞州諾伍德。有關Corbus的更多信息，請訪問corbuspharma.com。您也可以在Twitter、LinkedIn和Facebook上與我們聯繫。
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
前瞻性聲明
本新聞稿包含關於公司試驗結果、產品開發、臨床和監管時間表、市場機會、競爭地位、可能或假定的未來業務結果、商業戰略、潛在的增長機會以及其他預測性質的聲明，這些聲明符合1933年證券法第27(A)節和1934年證券交易法第21(E)節和私人證券訴訟改革法案的修改，這些聲明基於我們所在行業和市場的當前預期、估計、預測和投射，以及公司管理層的當前信念和假設。
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
這些聲明可能通過使用前瞻性表達式識別，包括但不限於「期望」，「預計」，「打算」，「計劃」，「認爲」，「估計」，「潛在」，「預測」，「項目」，「應該」，「會」 和類似的表達式以及這些術語的否定形式。這些聲明涉及未來事件或我們的財務表現，並涉及我們的運營，臨床開發計劃和時間表上已知和未知的風險，不確定性和其他因素，可能導致實際結果，績效或成就與前瞻性聲明中表達或暗示的任何未來結果，績效或成就實質上不同。此類因素包括在公司提交的與證券交易委員會的文件中所述。未來投資者應該注意不過分依賴這些前瞻性陳述，這些陳述僅在本新聞稿發佈之日有效。公司不承擔更新任何前瞻性陳述的義務，無論是因爲新信息，未來事件還是其他原因。
All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.
所有產品名稱，標誌，品牌和公司名稱均爲其各自所有者的商標或註冊商標。其使用不意味着這些公司的隸屬或認可。
INVESTOR CONTACT:
投資者聯繫：
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com
Sean Moran
首席財務官
Corbus製藥公司
Sean.moran@corbuspharma.com
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
Bruce Mackle
常務董事
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
譯文內容由第三人軟體翻譯。